Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.38 |
| ▸ | DHODH | Q02127 | 4/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21543515 | 1.00 | KRAS (0.38) | KRASDHODHMAPK8EIF4ENPC1 | |
| SCHEMBL21530982 | 0.81 | KRAS (0.46) | KRAS | |
| SCHEMBL21543230 | 0.79 | MAPK8 (0.38) | MAPK8 | |
| SCHEMBL31745394 | 0.79 | MAPK8 (0.38) | MAPK8 | |
| SCHEMBL23234729 | 0.77 | KRAS (0.43) | KRAS | |
| SCHEMBL23234890 | 0.77 | KRAS (0.44) | KRAS | |
| SCHEMBL23234730 | 0.77 | KRAS (0.43) | KRAS | |
| SCHEMBL23583847 | 0.77 | KRAS (0.44) | KRAS | |
| SCHEMBL29469145 | 0.77 | KRAS (0.44) | KRAS | |
| SCHEMBL21543189 | 0.77 | KEAP1 (0.53) | DHODHEIF4ENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KRAS 1/4885DHODH 1093/4885MAPK8 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.